Abbott Laboratories (NYSE:ABT) stock rose Thursday after the healthcare company reported second-quarter 2026 results that beat Wall Street estimates on both earnings and revenue and raised its full-year adjusted earnings outlook.
Adjusted earnings came in at $1.31 per share, topping the analyst consensus estimate of $1.28.
Revenue increased 13% year over year to $12.59 billion, ahead of analysts' expectations of $12.50 billion.
On a comparable basis, sales rose 4.8%.
Read Also: Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise Medical Devices Drive Growth Medical Devices remained Abbott's largest growth engine, with sales rising 9% on a reported basis to $5.85 billion, or 8.4% on a comparable basis.
